Hims & Hers (HIMS) stock slid Wednesday, a day after the company announced new weight-loss drug offerings — an update that left investors unimpressed. Shares of the digital healthcare platform ...

You know Hims, right? It's the next-gen telehealth startup famous for taking the eye contact out of erectile dysfunction treatment. Of course, bedroom pills aren't all Hims peddles. The Uberized ...

(Reuters) - (This April 1 story has been corrected to say that the company also offers the branded version of Wegovy, not just cheaper versions of the treatment, in paragraph 3. It was previously ...

Hims & Hers Health HIMS-10.35%decrease; red down pointing triangle said it is expanding its weight-loss offerings with the addition of Eli Lilly LLY-3.56%decrease; red down pointing triangle & Co ...

Hims & Hers is shutting down the dermatology business it acquired in 2021, BI has learned. It said it's closing the skincare site Apostrophe to centralize its teledermatology offerings. Hims ...

The bump followed a very bullish Tuesday trading session for the stock. The company continues to plow into the retail segment with products that should be popular. The great opportunities in the ...

Hims & Hers Health announces that it's expanding access to personalized weight loss care. Hims & Hers will offer both Lilly's Zepbound and Mounjaro on its platform, as well as generic versions of ...

Hims & Hers Health shares jumped Tuesday as the company added Eli Lilly’s weight-loss drug Zepbound and diabetes treatment Mounjaro to its telehealth platform. The treatments will each cost $ ...

Eli Lilly and Company is the world's most valuable Pharma thanks to tirzepatide, a groundbreaking GLP-1 weight-loss and Type 2 Diabetes drug, marketed and sold as Zepbound / Mounjaro. Hims & Hers ...